Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
2 Months : From Oct 2019 to Dec 2019
By Kimberly Chin
Gilead Sciences Inc. (GILD) is scheduled to report results for its fiscal third quarter postmarket on Thursday. Here's what you need to know:
EARNINGS FORECAST: Analysts on average expect an adjusted profit of $1.74 a share, compared with $1.84 a share in the same quarter a year ago, according to a FactSet poll. Gilead Sciences will hold its investor call at 4:30 p.m. ET.
REVENUE FORECAST: Analysts expect $5.61 billion, per FactSet, roughly flat from a year ago. In July, Gilead Sciences raised the high end of its sales target by $300 million for the year.
WHAT TO WATCH:
GALAPAGOS COLLABORATION: In July, the company said will pay about $5.1 billion to boost its stake in Galapagos NV (GLPGF) to 22%. The move, which represents the companies' second collaboration, also helps Gilead develop and market Galapagos drugs outside Europe.
BIKTARVY: HIV-drug Biktarvy, which is one of the most prescribed HIV regimens in the U.S., helped boost sales in the company's previous quarter. Sales rose to $1.12 billion in the second quarter from $185 million last year.
Write to Kimberly Chin at firstname.lastname@example.org
(END) Dow Jones Newswires
October 23, 2019 20:12 ET (00:12 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.